AbbVie options integrin-based compounds from Morphic, paving way for potential fibrosis treatments

The biotech announced Tuesday morning that AbbVie has exercised a licensing option as part of that 2018 agreement, giving the pharma exclusive rights to two integrin inhibitors programs for idiopathic pulmonary fibrosis and other fibrosis-related diseases. Morphic will receive a $20 million licensing fee with potential future milestone payments.